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The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated
organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better
conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines,
andtheinclusionof adjuvantsand/ortheuse ofvaccine delivery systemsisalmostalwaysneeded. Among vaccinedelivery systems,
micro- and nanoparticulated ones are attractive, because their particulate nature can increase cross-presentation of the peptide.
In addition, they can be passively or actively targeted to antigen presenting cells. Furthermore, particulate adjuvants are able to
directly activate innate immunesystemin vivo. Here, we summarize micro- and nanoparticulated vaccine delivery systems used in
the ﬁeld of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity.
1.Introduction
Inrecentyears,therehasbeenanincreaseinthedevelopment
of vaccination technology, but the ideal vaccine has not
already been found. In general terms, there are some criteria
which a vaccine must satisfy; it must be capable of eliciting
the appropriate immune response, and it should be safe,
stable, and reproducible. There are other issues such as cost,
number of administrations, or immunization route which
m a ya l s oh a v et ob et a k e ni n t oa c c o u n t[ 1]. Traditional
vaccines have been developed using live attenuated organ-
isms (such as BCG—Bacillus Calmette-Guerin, measles,
mumps, rubella, and varicella), killed or inactivated whole
organisms (e.g., inﬂuenza) or inactivated toxins (including
diphtheria and tetanus) [2]. Livevaccines havethe advantage
of producing both humoral and cellular immune responses
and often require only one boost. However, these vaccines
are environmentally labile and require refrigeration, making
diﬃcult the delivery of these therapeutic agents, especially in
the developingcountries. Furthermore, the use ofattenuated
pathogens can revert to a more active form, a danger partic-
ularly acute in immune-compromised individuals [3]. Killed
orinactivatedorganisms generateaweakerimmuneresponse
and typically require multiple doses [4]. Hence, these types
of vaccines generally require the addition of an adjuvant to
be eﬀective [5]. These disadvantages led to the development
of subunit vaccines, including synthetic peptides as antigen,
which consist of a speciﬁc part of the whole pathogen which
has been demonstrated to stimulate an immune response.
These vaccines are attractive, because they cannot revert
to their virulent form and can be produced in bulk, safely
and reproducibly. However, subunit vaccines have relatively
low immunogenicity [6] which makes necessary the use of
adjuvants and/or vaccine delivery systems. Besides, protein-
based vaccines may be degraded by protease activity and
havelimitedbioavailability,sincetheyoftencannotcrossbio-
logical membranes [7, 8]. Finding the optimal combination
between a given synthetic peptide and an adjuvant opens
an unlimited clinical potential for these vaccines, because
if adequate epitopes were identiﬁed for a certain disease,
antigens could be synthesized on demand. For this reason,
successfuladjuvantsneedtobesafeandwelltolerated,simply
produced and with inexpensive compounds, biodegradables,
compatibles with many diﬀerent antigens, and capable of
function as a delivery system and immune potentiators [9].
Therefore, forlicensing ofnew ornewlyformulatedvaccines,2 Journal of Drug Delivery
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Figure 1: Schematic overview of the immune response developed after vaccination with micro- and nanoparticles entrapping antigenic
peptides.
nonclinical and clinical data regarding safety and eﬃcacy are
required, next to pharmaceutical quality data. These data are
needed on the active ingredients, as well as the adjuvants
and delivery systems, and their combination in the ﬁnal
product [10]. In this regard, there is only one guideline
speciﬁcally dedicated to peptides, Guidance for Industry for
the Submission of Chemistry, Manufacturing, and Controls
Information for Synthetic Peptide Substances, published in
1994 [11], which stipulates the lot release speciﬁcations
(suﬃcient to ensure the identity, purity, and strength of the
peptide and demonstrate lot-to-lot consistency).
The need of eliciting both humoral and cellular immune
responses has limited the eﬃcacy against certain pathogens,
such as malaria and HIV [3]. Activating the cytolytic
immune response (CTL)isneededin the case ofintracellular
pathogensor tumors, and it is mediated by CD8T cells, CD4
Th1 cells and natural killer T cells. Dendritic cells (DCs)
have several innate features that make them ideal targets
for vaccination purposes. They can capture antigens that
enter the body and move to the T cell areas of lymphoid
organstoﬁndtherightclonesandstarttheimmuneresponse
[10]. In peripheral tissues, DCs are found in an immature
stage specialized in capturing foreign antigens. In response
to microbes, DCs undergo a process of maturation into
antigen-presenting cells (APCs). Meanwhile, they migrate
from the periphery to the draining lymph nodes, where they
present antigens to the T lymphocytes. DCs can present
peptides to the T cells in the context of major histocom-
patibility complex (MHC) classes I and II molecules and
also glycolipids and glycopeptides to T cells and NKT cells
as well as polypeptides to B cells [12]. In order to achieve
a CTL response, cytolytic cells must speciﬁcally recognize
pathogen-derivedantigenspresentedinMHCclassIorinthe
CD1-lipidcomplex.Uponantigen recognition,immunecells
release cytolyticagentsthatdirectly destroy infected cellsand
can induce inﬂammatory reactions which facilitate innate
immune clearance and the development of some humoral
response.
In order to generate CD8+ T cell immune responses
cross-presentation have to occur, in which an exogenous
antigen is presented into MHC I molecules in order to pro-
mote strong cytolytic and Th1 inﬂammatory bias [3]. Most
protein-based vaccines do not develop cytolytic responses,
because they are more readily processed into MHC class II
molecules (which triggers humoral or antibody-dependent
immune responses) [13]. For the development of a CTL
response, antigens have to escape from the endosomal
compartment into the cytosolic and endoplasmic reticular
space, where the cross-presentation occurs [3]. Micro- and
nanoparticle-based vaccine delivery systems can function as
antigen carriers. Their particulate nature has some inherent
ability to facilitate antigen cross-presentation [3], since they
resemble pathogens particulate structure that looks like the
biological situation. Particles per se are passively directed to
the APCsand can increase theinteraction between thesecells
and the antigen due to particles slow degradation [1]. Apart
from the depot eﬀect, particulate adjuvants can directly
activate innate immunity in vivo [14]; that is, they work asJournal of Drug Delivery 3
immunoadjuvants. Thus, modiﬁcation of these systems to
directly target APCs may be a good approach for improving
their eﬃcacy. Therefore, micro- and nanoparticulated deliv-
ery systems can lead good opportunities in the development
of synthetic peptide-based vaccines (Figure 1).
When preparing micro- or nanodevices, there are some
key formulation aspects such as chemical composition and
manufacturing process, which aﬀect the antigen loading
capacity and release proﬁle, product stability, eﬃcacy, and
safety [15]. For instance, the diﬀerence in size between
micro- and nanoparticles may change the immune response
achieved. The smaller the particle, the greater the proportion
of drug located on its surface. This can lead to a substantial
loss of payload or to a lower maximal drug loading for
smaller particles [16], which ﬁnally may aﬀect to the adju-
vant activity. Moreover, the preparation process of micro-
and nanoparticles can lead to stability problems due to the
exposure to strong stress conditions (e.g., aqueous/organic
interfaces, hydrophobicsurfaces, and vigorousshaking)[17].
For this reason, peptide stability, once entrapped into the
formulation, should be evaluated, since it is unlikely to
develop a universal encapsulation approach appropriate to
every peptide. For instance, in order to study the stability of
the SPf66 peptide encapsulated into PLGA MPs, Carcaboso
et al. [18] analyzed peptide integrity by polyacrylamide
gel electrophoresis and showed no bands indicating partial
degradation or aggregation of the protein.
Nowadays, there are no marketed vaccines composed
of synthetic peptides. However, there are approved vaccines
based on micro- and nanotechnologies. Alum is the most
widely used adjuvant for human vaccines in the form of par-
ticulated aluminium salts (generally, Al(OH)3 and AlPO4)
[19]. As shown in Table 1, it is used in various vaccines,
such as the combined vaccine containing antigens against
diphtheria, tetanus, and pertusiss [20] and against hepatitis
B( R e c o m b i v a xH B[ 21]o rE n g e r i xB[ 22, 23]). More
recently, other particulate adjuvants have been licensed for
human use.EmulsionslikeMF59orAS03are componentsof
Fluad and Pandemrix, respectively [24, 25]. Other vaccines
such as Epaxal [26]o rI n ﬂ e x a l[ 27] include virosomes.
Latest approved systems are composed of combination of
adjuvants, such as AS04 (approved for human use in both
Europe and USA), which comprises MPL (monophosphoril
lipid A) and alum and is used into Fendrix [28]o rA S 0 4
combined with virus like particles (VLPs) used into Cervarix
[29, 30]a n dG a r d a s i l[ 31].
This paper summarizes micro- and nanoparticulated
delivery systems used in the development of synthetic
peptide-based vaccines. We also discuss various strategies
f o ri m p r o v i n gt h e i re ﬃcacy in developing an appropriate
immune response (Table 2).
2.Micro- and NanoparticulatedSystemsfor
SyntheticPeptideVaccineDevelopment
2.1. Alum. Aluminium salts (generally, Al(OH)3 and
AlPO4), often called alum, have been widely used in humans
for more than 80 years, and, until recently, it has been the
only adjuvant approved for human use in the USA [32].
Currently, there are many vaccines containing alum, such as
RecombivaxHBorEngerixB.Alumadjuvancityis associated
with enhanced antibody responses [19]. It has been shown
that after OVA-alum administration Th2 eﬀector response is
generated, as T helper cells produced IL-4, IL-5, and IL-10
but little IFN-γ [33]. In addition, Li et al. demonstrated that
alum enhances the production of IL-10, a Th2 cytokine,
and inhibits that of IP-10 (IFN-γ-inducible protein), a
chemokine speciﬁc for Th1 cells [34]. It has been shown
that alum induces rapid cell recruitment at the injection
site. Kool et al. demonstrated that after an intraperitoneal
injection of alum, a local production of chemoatractants like
CCL2 and CXCL1 was triggered, as well as a recruitment of
neutrophils, eosinophils, monocytes, and subsequently DCs.
This study also revealed that following intraperitoneal or
intramuscular administration of alum, recruited monocytes
migrate to the draining lymph nodes and diﬀerenciate into
inﬂammatory DCs capable of priming T cells [33].
Several action mechanisms have been proposed in order
to explain alum adjuvancity. Previously, it was thought that
alum formed a depot by which the antigen was slowly
released and which converted the antigen into a particulate
form, facilitating phagocytosis by APCs [35]. Later, it has
been shown that alum induces inﬂammatory responses
that recruit and activate APCs which capture the antigen
[34]. Recent data demonstrate that alum targets NOD-like
receptor protein 3 (NLRP3 or NALP3) to mediate caspase-
1a c t i v a t i o na n dI L - 1 β release in lipopolysaccharide- (LPS-)
primed macrophages [36]. NLRP3 interacts with Cardinal
and ASC (apoptosis-associated speck-like protein) to form a
caspase-1-activating complex called inﬂammasome, which,
in turn, mediates the activation of proIL-1β, proIL-18, and
proIL-33 into their active forms (Figure 2)[ 34]. However,
in vivo data demonstrated that NLRP3 is dispensable for
the adjuvant activity [36]. Nevertheless, other groups have
reached conﬂicting conclusions. Eisenbarth et al. [37]a n d
Li et al. [38] found an abrogation of the antibody responses
to coadministered antigen in absence of NALP3 signaling,
whereas Kool et al. [39] found only partial inhibition of the
response. However, these results may beexplained by thefact
that diﬀerent alum formulations were used in each study or
diﬀerent levels of TLR (Toll like receptor) agonist were used
[40].
Other studies have suggested that NALP3 could be
stimulated though indirect mechanisms. Kool et al. found
that following alum administration, an increase in the
endogenous danger signal uric acid happened. Neutraliza-
tion of uric acid with uricase led to an inhibition of the
inﬂammatory response induced by alum [33].
There are several investigators which study the immune
response achieved after combining synthetic peptides with
alum.Forinstance, aphaseIclinicaltrial was conductedwith
the long synthetic peptide GLURP85-213 of Plasmodium
falciparum combined with either alum or Montanide ISA
as adjuvants [41]. Formulations were administered subcuta-
neously with 10, 30, or 100μg peptide doses at days 0, 30,
and 120. Although serious adverse events were not observed,
adverse events were more prevalent in the Montanide ISA4 Journal of Drug Delivery
Table 1: Examples of EMA- and/or FDA-approved vaccines based on micro- and nanoparticulated delivery systems. MF59 and AS03
are squalene- and tocopherol-based o/w emulsions, respectively. AS04 is composed of monophosphoril lipid A and alum. Virosomes are
composed of viral-derived phospholipid bilayers, and virus-like particles (VLPs) are viral capsids lacking genetic material.
Vaccine Delivery system Indication Reference
Recombivax Alum Hepatitis B [17]
Engerix B Alum Hepatitis B [18, 19]
Tripedia, Infanrix, DAPTACEL Alum Diphteria, Tetanus and Pertussis [16]
Fluad MF59 Inﬂuenza/pandemic ﬂu [20]
Pandemrix AS03 Pandemic ﬂu [21]
Fendrix AS04 Hepatitis A [24]
Epaxal Virosomes Hepatitis A [22]
Inﬂexal Virosomes Inﬂuenza [23]
Cervarix AS04 + VLPs Human papillomavirus [25, 26]
Gardasil VLPs + Alum Human papillomavirus [27]
Table 2: Schematicview ofthe mechanism ofactionand advantages ofthe diﬀerent micro- andnanotechnologies forpeptide-based vaccine
delivery.
Type of technology Role Advantages
Alum (i) Depot
(ii) Activation of inﬂamasomeand IL-1β release (i) Enhances antibody responses
Emulsions (i) Promote antigen uptake by DCs
(ii) Strong immunostimulatoryactivity
(i) Allows reduction of antigen dose
(ii) Well tolerated
(iii) Useful in children
(iv) Mixed Th1/Th2 responses
Polymeric MPs and NPs (i) Enhance IL-1β secretion by DCs
(i) Biodegradable and biocompatible
(ii) Release during long time periods
(iii) Modulation of the delivery: continuous, by
pulses, or triggered by several factors (pH,
temperature, ionic strength, electric or magnetic
ﬁelds)
(iv) Elicit humoral and cellular immunity
Liposomes (i) Passive targeting
(ii) Tendency to interact with macrophages
(i) CD4+,C D 8 + and CLT immune responses
(ii) Modulation of the immune response using
diﬀerent lipids
VLPs (i) Taken up by APCs and MHC class I and II
presentation
(i) Incorporation of peptides produced by
recombination, or chemically coupling them
once the VLP is formed
(ii) Potent humoral and cellular immune
responses
Virosomes (i) Enter cells through receptor mediated
endocytosis
(i) Membrane fusion properties of the virus are
maintained
(ii) Humoral and CTL responses
(iii) Value for developing multivalent vaccines
ICOMs and ISCOMATRIX
(i) Antigen carrier
(ii) Immunostimulation(because of the
saponin)
(i) Potent humoraland cellular immune
responses
(ii) Reduction of the antigen dose
(iii) Safe and well tolerated
Nanobeads
(i) Depends on the size: small ones elicit CD8+
immune response, whereas larger ones facilitate
CD4+ responses
(i) Humoral and cellular immune responsesJournal of Drug Delivery 5
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Figure 2: Scheme of the potential interaction of alum with the
NALP3 inﬂammasome. Caspase-1 is activated, which in turn, pro-
motes the activation ofproinﬂammatorycytokines IL-β, IL-18, and
IL-33. This process is abrogated by actin polymerization inhibitors,
suggesting that activation of NALP3 requires phagocytosis.
group. On the other hand, both vaccines generated anti-
bodies with capacity to mediate growth-inhibitory activity
against P. falciparum in vitro.
However, nowadays, alum adjuvant is being replaced by
other systems that improve the immune response achieved,
and generally, it is used as a control or in combination with
other adjuvants. For example, Raman et al. investigated the
immunomodulatory eﬀects of two types of CpG adjuvants
intranasally administeredwithﬁvesyntheticpeptideantigens
of Plasmodium vivax in alum and microparticles. The
addition of alum to CpG increased four-fold the antibody
t i t e r sa n dt r i g g e r e dap r e d o m i n ance of IgG2a/2b isotypes.
High titers against one of the peptides have a signiﬁcant
inhibitory eﬀect on parasite development in the mosquito
and the peptide-speciﬁc antisera reacted with the air-dried
parasite antigens isolated from P. vivax patients [42].
2.2. Emulsions. Adjuvants composed of emulsions include
oil in water (o/w) and water in oil (w/o) systems. There are
two formulations approved for human use in Europe, MF59
and AS03. There is also another compound, Montanide,
under phase III stage trials.
MF59, a squalene-based o/w emulsion is licensed for
inﬂuenza vaccine (Fluad). Vaccines with MF59 are safe and
have demonstrated a better immunogenicity than nonadju-
vanted ones, even in the elderly [44] and childhood [45].
Evaluation of safety data of 64 clinical trials involving MF59
UPV/EHU SEI 5kV ×1000 10μm WD 6mm
Figure 3: Scanning electron micrograph of PLGA microparticles
(×10,000).
revealed that MF59 adjuvanted subjects had lower risks
than nonadjuvanted ones of undergoing unsolicited adverse
events. On the other hand, MF59 adjuvanted subjects had
a higher risk of expected local (mild or moderate pain,
injection-site warmth induration,and erythema) orsystemic
reactions (myalgia, headache, fatigue, and malaise) [46]. The
eﬀects of the exposure to MF59 during pregnancy have also
been evaluated. Tsai et al. analysed the clinical trial database
ofNovartisVaccinestudiesfrom1991to2009andfoundthat
distribution of pregnancy outcomes (normal, abnormal, or
ending in the therapeutic abortion) was similar in subjects
exposed to MF59 compared to non exposed ones at any time
of pregnancy, speciﬁcally in early pregnancy [47]. Although
these data are few to draw deﬁnitive conclusions, available
observations, so far, indicate no signal of risk.
Despite the wide use of MF59, its mechanism of action is
not well understood. Immunoﬂuorescence analysis showed
that MF59 promoted antigen uptake by DCs after intramus-
cular injection [48], which suggest that its adjuvancity is not
mediated by a depot eﬀect. A study comparing the adjuvant
eﬀect of MF59, alum and CpG, characterized the changes
in the expression of genes after intramuscular injection
in mice. MF59 was the stronger inducer of cytokines,
cytokinereceptors, adhesionmoleculesinvolvedinleukocyte
migration, andantigenpresentationgenes[49].Inthisstudy,
it was hypothesised that MF59combines the antigen delivery
function with strong immunostimulating activity. Moreover,
it may also promote a sustained antigen-presentation trig-
gering the recruitment of CD11b+ monocytes, which might
diﬀerentiate in functional inﬂammatory DCs, expressing
high levels of MHC class II, as previously described for alum
[33].
AS03 is a tocopherol o/w emulsion-based adjuvant used
in Pandemrix, an inﬂuenza pandemic vaccine. Clinical trials
have demonstrated that AS03 adjuvanted vaccines are able
to trigger an immune response comparable to that obtained
with nonadjuvanted ones using a fourfold lower dose [50].
Inaddition,thevaccineiswelltolerated,andsolicitedadverse
eventsaretransientandmainlymildtomoderateinintensity.6 Journal of Drug Delivery
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Therefore, a high reduction in the dose of haemagglutinin
can be achieved and can induce cross-clade immunity
in humans, a prerequisite for an eﬀective prepandemic
vaccination strategy [51–53]. Moreover, a recent clinical trial
suggests that Pandemrix used in children 6–35 months old is
highly immunogenic and that overall reactogenicity proﬁle
is acceptable although reactions including fever tend to
increaseafteraseconddose[54].However,toourknowledge,
no study has been published that combines the use of
synthetic peptides and MF59 or AS03.
Montanide is a w/o emulsion-based adjuvant. Although
it is not yet approved for human use, lot of clinical trials
are undergoing against several diseases such as malaria,
melanoma, ornonsmall celllungcancer[55].AstudycarriedJournal of Drug Delivery 7
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Figure 7: Electron micrograph of ISCOMATRIX adjuvant follow-
ingnegative staining.ISCOMATRIX adjuvant particles are typically
rigid,hollow,spherical,andcage-likeparticlesapproximately40nm
in diameter. Reproduced with permission from [43].
out in our laboratory, compared the immune response
against the S3 malarial synthetic peptide using Mon-
tanide, poly-lactide-co-glicolide (PLGA) microparticles and
aluminium hydroxide. Subcutaneously administered Mon-
tanide and microspheres resulted in eﬀective adjuvants and
revealed mixed Th1/Th2 immune responses [56]. However,
inapreviousstudyitwasshownthatMontanidewaseﬀective
inelicitingantibodiesagainstthe3D7peptidebutnotagainst
the FC27 peptide [57]. In addition, a recent clinical trial
has been carried out to evaluate the safety, tolerability, and
immunogenicity of mixtures of N, R, and C long synthetic
peptides derived from the P. vivax circumsporozoite protein
formulated in two types of Montanide (ISA 720 and ISA 51)
[58]. However, the results of this study are not yet published.
2.3. Polymeric Micro- and Nanoparticles. Polymeric micro-
and nanoparticle-based vaccine delivery systems have been
widely studied. The most commonly used polymers are
poly(D,L-lactic-co-glycolic) acid (PLGA) and its derivates
(Figure 3), due to their inherent advantages over other
systems. They are biodegradable and biocompatible, are able
to release molecules during long periods of time (weeks
or months), and they are ease to administer via injection
[59]o ro r a l l y[ 60]. In addition, PLGA has been approved
for human use in sutures [61], bone implants [62], and
screws [63]a sw e l la si ni m p l a n t sf o rs u s t a i n e dd r u gd e l i v e r y
[64]. Apart from PLGA, other polymers have also been used
for vaccination purposes, such as alginate [65], chitin [66],
albumin [67], sodium polyacrylate [68], chitosan [69], poly-
ε-caprolactone [70], or poly(γ-glutamic acid) [71]a sw e l la s
some polymer combinations [72, 73].
In these formulations, the antigen can be either
entrapped or adsorbed on the surface of the particles. The
delivery of the antigen canbe slow and continuous, by pulses
or it can be triggered by external or environmental factors
such as changes in the pH [74], temperature [75], ionic
strength [76], or electric and magnetic ﬁelds [77].
T h ep a r t i c l es i z ea n ds i z ed i s t r i b u t i o na r ei m p o r t a n t
factors to determine antigen release rate, as the total surface
area for protein delivery depends on the particle size [78].
With regard to particle size, it has been shown that it
can inﬂuence the type of immune response achieved. In
fact, nano- and microparticles (NPs and MPs) do not have
the same behaviour in vivo. Kanchan and Panda showed
that HBsAg-loaded polylactide MPs (2–8μm) elicited higher
and long-lasting antibody titers and were not taken up by
macrophages but were on their surface. In addition, MPs
promoted IL-4 secretion and upregulation of MHC class II
moleculesand favoured Th2 immune response. On the other
hand, NPs (200–600nm) were eﬃciently phagocytized by
macrophages and elicited lower antibody titers, but higher
levels of IFN-γ production, upregulation of MHC class
I molecules along with antibody isotypes favouring Th1-
type immune response [79]. Moreover, Manolova et al.
demonstrated that intradermally administered small-sized
polystyrene particles (≤200nm) were rapidly transported
to the lymph nodes, where they were taken up by resident
DCs.Incontrast,largeparticles(500–2000nm) dependedon
cellulartransport byskinDCs[80].Despitethesediﬀerences,
it is not clear which type of particle would be better for each
particular case; therefore, particle size would be individually
studied.
On the other hand, the administration route of particles
may inﬂuence the immune response elicited. Mohanan et
al. [81]h a v es t u d i e dt h eb i a so ft h ei m m u n er e s p o n s e
in mice when immunised by diﬀerent routes, such as
the subcutaneous, intradermal, intramuscular, and intra-
lymphatic routes with ovalbumin-loaded liposomes, N-
trimethyl-chitosan NPs and PLGA MPs, all with and without
immune-response modiﬁers. This study has demonstrated
that the IgG2a associated with Th1 immune response is sen-
sitive to the route of administration, whereas IgG1 response
associated with Th2 response was relatively insensitive to the
administration route of particulate delivery systems.
Regarding to the mechanism of action, it has been
shown that similarly to alum, PLGA microspheres enhance8 Journal of Drug Delivery
IL-1β secretion by DCs, in addition to trigger caspase-1
activation. These abilities require particle uptake by DCs
and NALP3 activation [82]. Although the presence of a
TLR agonist was required to induce IL-1β release in vitro,
injection of the particles in the absence of a TLR agonist
induced IL-1β production at the injection site, indicating
that endogenous factors can synergize with particles to pro-
mote inﬂammasome activation. This study also showed that
the enhancement of antigen-speciﬁc antibody production
by microparticles was independent of NALP3, but it was
needed in order to microspheres promote antigen-speciﬁc
IL-6 production by T cells and recruitment and activation
of CD11b+ Gr1− cells. However, other studies showed that
administration of LPS-modiﬁed PLGA microspheres loaded
with antigen (ovalbumin), were preferentially internalized
by DCs compared to nonmodiﬁed particles. In addition,
theseparticleselicitedpotenthumoralandcellularimmunity
againstovalbumin,andwild-typemacrophagesincreasedthe
release of IL-1β, consistent with inﬂammasome activation
[83]. These data highlight that there is still controversy
with the mechanism of action of polymeric micro- and
nanoparticles.
PLGA micro- and nanospheres can be used for systemic
or mucosal immunization [84–86]. PLGA-based systems are
able to be phagocytosed by DCs, even by the oral route [87]
andenhancetheirimmunostimulatory capacity[88],leading
to the upregulation of maturation markers CD40 and CD80
and release of IL-6. It has been shown that Hp91 synthetic
peptide (a peptide that can induce potent antigen-speciﬁc
cytotoxic T-lymphocyte responses), both encapsulated or
conjugated to the surface of PLGA nanoparticles, is able to
activate bothhuman and mouse DCsmore potently than the
free peptide [88].
PLGA microspheres have been extensively studied by
our research group. Diﬀerent synthetic peptides have been
entrapped into these microspheres, such as malarial SPf66,
and have been administered by subcutaneous, intradermal
[89], oral [17], or nasal [90] routes in mice. Microencap-
sulated SPf66 induced a superior immune response than
the one obtained with the administration of the peptide
adjuvanted with alum and comparable with the response
obtained with FCA. In addition, these particles have been
administered to Aoutus monkeys leading to high antibody
levels and protection against P. falciparum challenge [91].
To ourknowledge, only one clinical trial has beencarried
out using PLGA and synthetic peptides [92]. This phase I
study evaluatedthesafety and immunogenicityof a synthetic
HIV peptide (HIV-1 MN V3) administered intramuscularly
with alum and a similar product encapsulated into PLGA
microspheres administered by the oral route. However, the
oral administration of this vaccine did not trigger signiﬁcant
humoral, cellular, or mucosal immune responses.
2.4. Liposomes. Liposomes are synthetic spheres comprised
by phospholipid bilayers (Figure 4). According to their
structure and size, liposomes can be classiﬁed into multi-
lamellar vesicles (MLV), small unilamellar vesicles (SUV),
intermediate unilamellar vesicles (IUV), or large unilamellar
vesicles (LUV) [93]. For vaccine delivery, antigens can be
encapsulated into the aqueous core, integrated in the lipid
b i l a y e ro ra d s o r b e do nt h es u r f a c e[ 4].
The mechanism of action of liposomes is not well
deﬁned. Passive targeting, derived oftheir particulate nature,
and tendency to interact with macrophages is likely to be
an important factor, particularly for nontargeted liposomes
[94]. Among the diﬀerent lipids available, cationic ones
have a better ability to initiate and potentiate the immune
response. It has been shown that positive charge is an
important factor for the retention of liposomes at the
injection site. Neutral liposomes have been shown limited
in their ability to mediate long-term antigen presentation
to circulating antigen-speciﬁc T cells and to induce the
Th1 and Th2 arms of the immune system, as compared
to cationic liposomes. The neutral liposomes did, however,
induce the production of IL-5 at levels comparable to
cationicliposomes, indicating thattheycaninduceweak Th2
response [95].
Liposomes composition may also aﬀect the type of
immune response achieved. The inclusion of a fusogenic
lipid in the formulation (i.e., easily fuses with the lipid mem-
branes), such as DOPE, leads to superior IgG2a response
against OVA, indicative of directing towards a Th1 response
[96].
Coupling antigens to the liposomal surface can lead to
CD4+,C D 8 + T, and CTL immune responses. CTL epitopes
composed of synthetic peptides derived from severe acute
respiratory syndrome (SARS) coronavirus (SARS-CoV) and
coupled to the surface of liposomes were eﬀective for
peptide-speciﬁc CTL induction in mice. One of these pep-
tides was also able to clearance vaccinia virus which expresed
epitopes of SARS-CoV after a challenge, suggesting that
surface-linked liposomal peptides might oﬀer an eﬀective
CTL-based vaccine against this disease [97]. On the other
hand, it has been demonstrated that even small amounts
of antigen entrapped into liposomes can induce IgG2a
antibodies, the vias towards Th1 is more pronounced when
more antigen is entrapped [96].
Liposomes can also induce antigen-speciﬁc antitumor
immunity. Liposomes grafted to synthetic peptides derived
from DCs maturation signals, such as HMGB1 (high-
mobility group box 1), are able to target macrophages and
DCs in vitro and in vivo. Coupling these liposomes to tumor
derived plasma membrane vesicles inhibited tumor growth
and metastasis after a tumor challenge in mice [98].
2.5. Virus Like Particles and Virosomes. Virus like particles
(VLPs) are obtained when viral structural proteins are
produced in recombinant expression systems or even in cell-
free systems [99, 100]. Recombinant viral structural proteins
of several viruses can spontaneously assemble into VLPs in
the absence of the viral genetic material and other viral
proteins, which makes them non infectious (Figure 5). VLPs
are able to incorporate peptide vaccines, either produced
by recombination (genetically fused to the gene which
encodes for the VLP), or chemically coupling peptides to
the formed VLP [101, 102]. Pejawar-Gaddy et al. generated
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coupled to a synthetic derivate of MUC1 (human mucin-
1) peptide [103]. This peptide is aberrantly expressed on
a wide range of ductal adenocarcinomas and has been
intensively studied as a candidate cancer vaccine antigen.
MUC1-conjugated VLPs were subcutaneously administered
to MUC1 transgenic mice, leading to a robust activation of
bone marrow-derived DCs, which presented the antigen to
MUC1-speciﬁc T cells. In addition, immunization of human
MUC1 transgenic mice, where MUC1 is a selfantigen, with
the VLP vaccine induced MUC1-speciﬁc CTL, delayed the
growth of MUC1 transplanted tumors and elicited complete
tumorrejection insome animals. This studyand others[102,
104] demonstrate that VLP could be eﬃciently taken up by
APCs, leading to both MHC class II and I presentation. In
addition, VLPs are able to induce potent antivirus humoral
and cellular immune responses [105–107].
Several vaccines based on VLPs are currently approved
for human use (Gardasil and Cervarix), demonstrating
that VLP provide an appropriate immunity against papillo-
mavirus [27, 29, 108]. Moreover, other VLP-based vaccines
are under development, including vaccines against inﬂuenza
[109,110],HIV[111],orNorwalkvirus[112],andinclinical
trials [113].
Virosomes are similar to virus-like particles, consisting
of reconstituted viral envelopes lacking the viral genetic
material. They are generated from virus by a detergent
solubilization and reconstitution procedure [114]. The
main diﬀerence with VLPs is that VLPs are self-assembled
viral capside proteins, while virosomes use the envelope
phospholipid bilayers as a platform to which additional
viral components or antigens are attached (Figure 6)[ 4].
Virosomes may be produced from a variety of enveloped
viruses although the most used one is the inﬂuenza virus. In
fact, virosomal approved vaccines (Inﬂexal and Epaxal) are
composed of inﬂuenza virosomes [24, 25]. Inﬂuenza viro-
somes possess membrane fusion properties very similar to
the native virus, because they maintain the receptor-binding
and membrane fusion activity of the viral haemagglutinin.
Therefore, virosomes enter cells through receptor-mediated
endocytosis, but this process does not result in the infection
of cells, because virosomes lack the viral RNA [115].
Foreign macromolecules, including synthetic protein
antigens, can be encapsulated in virosomes during the
reconstitution process. These virosomes are able to induce
a powerful class I MHC-restricted CTL response, mainly
because they will deliver their content to the cell cytosol
[116], which favours the cross-presentation. This makes
virosomes possible to be used as a suitable delivery system
in tumor immunotherapy [117].
On the other hand, a fraction of the particles will
inevitably be degraded within the endosomal/lysosomal
compartment. The resulting peptides will be abletoassociate
with MHC II molecules, resulting in CD4+ response [116].
Development of antibody responses have been found upon
administration of malarial synthetic antigens containing
virosomes. In fact, IgG antibodies against UK-39(a synthetic
peptide derived from the circumsporozoite protein of P.
faciparum)inhibitedinvasion ofhepatocytesbyP. falciparum
sporozoites [118]. A second peptide (AMA49-C1) based on
domain III ofapical membrane antigen 1induced antibodies
that inhibited blood-stage parasite growth in vitro [119].
Combination of both antigens into diﬀerent virosomes did
not aﬀect negatively the antipeptide antibody titers in mice
or rabbits, demonstrating the value of this system for the
development of multivalent vaccines [120]. In addition,
a phase I clinical trial has been carried out in order to
evaluate the safety and immunogenicity of two virosome-
formulated P. falciparum derived synthetic peptide antigens
(AMA49-CPE and UK39)[121]. Bothvaccines resulted safe,
as no serious or severe adverse events were observed. In
terms of immunogenicity, both formulations elicited already
an antibody speciﬁc response in all volunteers with the
appropriate dose.
2.6. ISCOMS and ISCOMATRIX. Immunostimulatory com-
plexes (ISCOMs) are cage-like structures, approximately
of 40nm in diameter composed of antigen, cholesterol,
phospholipid, and saponin, held together by hydrophobic
interactions, so typically entrapped antigens are amphi-
pathic. The most commonly used saponin is QuilA or its
puriﬁed compounds [5, 122]. ISCOMATRIX has essentially
the same structure as ISCOMs but lacks the antigen, which
can be subsequently added (Figure 7). This fact provides
ISCOMATIX for more general applications as they are
not limited to amphipathic antigens [4, 122]. Although
numerous studies have been carried out with animal models
[123–126], few clinical trials evaluating ISCOMs and ISCO-
MATRIX are currently in course [127].
ISCOMs are not immunogenic by themselves although
other saponins diﬀerent from QuilA are used [43, 128],
but when the antigen is incorporated, they can trigger
humoral, mucosal, and cellular immune responses [128].
Diﬀerent results have been obtained when evaluating
ISCOMs immunogenicity. For instance, Agrawal et al. [129]
administered in the footpad of mice diﬀerent HIV-1 derived
synthetic peptides,withand withoutanimmunoadjuvant, in
liposomes or ISCOMs and compared to the administration
of peptides with alum. In contrast to alum, both liposomes
and ISCOMs induced a predominant Th1 like response. On
the other hand, Pahar et al. [123] found that intrarectal
immunization of macaques with two HIV-derived peptides
(HIV-1env and SIVgag) incorporated into ISCOMs induced
low level of immunity against simian-HIV. These diﬀerences
may be due to the antigens used, diﬀerences in the adminis-
tration route, dose, or schedule.
ISCOMATRIX adjuvant facilitates antigen delivery and
presentation as well as immunomodulation to provide
enhanced and accelerated immune responses. Moreover,
it is capable of inducing broad and potent humoral and
cellularimmune responses includingbothCD4+ and CD8+T
cell responses [130, 131]. The antibody response is often
achieved with lower amounts of antigen than with other
adjuvant systems [132]. Additionally, ISCOMATRIX adju-
vant can be used in vaccines for induction of mucosal
immune responses [133, 134]. In fact, protective ability of
ISCOMATRIX adjuvanted vaccines has been reported [135],
and theyhavebeen used in some veterinarian vaccines[136].10 Journal of Drug Delivery
ISCOMATRIX adjuvants are also eﬀective in the ﬁeld
of cancer treatment. NY-ESO-1 is a protein expressed in
many cancers.This recombinant protein with ISCOMATRIX
adjuvant has been evaluated in a clinical trial [137]d e m o n -
strating that the vaccine is safe and highly immunogenic.
Recently, Ebert et al. have studied the eﬀects of a NY-
ESO-1 peptide synthetic derivate (NY-ESO-160−72/HLA-B7
tetramer) with ISCOMATRIX in humans. They have found
that thisvaccine formulation allows DCstocross-present the
NY-ESO-160−72 epitope eﬃciently and generates a potent T
cell response.
Regarding tosafetyconcerns,Andersonetal.havepooled
and analyzed the safety data obtained from a number of
vaccine development programs comprising ISCOMATRIX.
Overall, the ISCOMATRIX vaccines were found to be safe
and well tolerated, with no vaccine-related deaths or serious
adverse events. Reactogenicity at the injection site was found
tobethemostfrequentadverseeventcomparedwithsubjects
who received placebo or active comparator; however, this
reactogenicity was generally mild, self-limiting, and of
short duration. Until the end of the study, ISCOMATRIX
vaccines have not been associated with events suggestive of
autoimmune or allergic disorders nor events of anaphylaxis
[138].
Recently, cationic immune stimulating complexes have
been developed (PLUSCOMs). In contrast to ISCOMs,
PLUSCOMs are able to incorporate hydrophilic peptides
adsorbed onto their surfaces by ionic interactions. In addi-
tion, they are as eﬀective as classic ISCOMs in inducing
antigen-speciﬁc CD8+ T cell responses [139].
2.7. Nanobeads. The use of nanobeads as vaccine car-
rier/adjuvant systems implies the coupling of solid inert
beads, generally made of carboxylated polystyrene, with
an antigen [5]. Beads of 40–50nm are better internalized
by DCs than higher ones and induce CD8+ type immune
response, whereas larger beads facilitate CD4+ response
[140].Otherstudiescarried outin vivo were in accordance to
this ﬁnding. Particles in this size range could elicit antibody
and cell immunity in mice, aswell as provideprotection after
a tumor challenge [9, 141]. Later, these ﬁndings were also
conﬁrmed in sheep [142, 143]. For instance, administration
of multiple synthetic peptides derived from foot-and-mouth
disease virus conjugated separately to individual nanobeads
or conjugated as a mixture, were able to induce signiﬁcant
cell-mediated and humoral immune responses in sheep
administered intradermally [143].
3.CurrentApproachesto Improve the
Immunogenicityof ParticulatedSystems
The development of successful vaccines implies the produc-
tion of an appropriate immune response against a given
pathogen. This approach concerns immunological, biotech-
nological, and pharmaceutical aspects, as the interaction
between DCs and T lymphocytes, selection of appropriate
antigens and adjuvants, and the production of an stable
end product must be taken into account [15]. In some
cases, vaccine delivery systems have been suﬃcient to
induce a long lasting protective immunity. However, poorly
immunogenic antigens, such as synthetic peptides, are often
unable to induce a protective immunity when incorporated
into delivery systems alone and require the incorporation
of immune potentiating molecules [8]. Immune potentia-
tors activate innate immune receptors of APCs (named
pathogen recognition receptors—PRRs), which recognize
pathogen associated molecular patterns (PAMPs). Among
PRRs,signalling receptorsactasprimary sensorofpathogens
and damage, and ﬁnally trigger both eﬀector and adaptive
immune responses. These receptors can be located on the
plasma membrane, in diﬀerent internal compartments, or in
membranes from intracellular vesicles, or can be cytosolic
proteins [144]. Three families of signalling receptors have
been identiﬁed: TLRs, NLRs, and RLRs. Members of TLR
family recognize bacteria, viruses, fungi and protozoa;
NLRs detect bacteria and RLRs are antiviral. It is likely
that interaction between these families provides synergistic
or cooperative signalling [145]. In addition, other PPRs
(humoral proteins and endocytic receptors) have a critical
role in activating antigen presentation [144, 146].
The activation of PRRs by immune potentiators induces
the secretion of proinﬂammatory cytokines and type I
interferon, the upregulation of costimulatory molecules and
MHC class II molecules. In addition, PRRs also trigger the
migration of APCs from the injection site to the T cell
areas of the draining lymph nodes. All these processes are
needed for activation of naive T cells and the developmentof
both humoral and cellular immune responses [147]. Thus,
formulation of vaccines that target PRRs is an interesting
approach in order to improve their immune response.
Traditionally, antigens have been formulated into their
soluble form plus an immune potentiating molecule [148,
149]or were entrapped into delivery systems alone [89, 150].
Current tendency is to combine more than one adjuvant into
the same vaccine formulation in order to achieve the desired
immune response.
3.1. Combination of Adjuvants with Diﬀerent Action Mech-
anism. It has been shown that combination of adjuvants
can increase the immune response. For this reason, most of
the novel vaccine formulations comprise a combination of
adjuvants.
Themostcommoncombinationofadjuvantswithdiﬀer-
ent action mechanism is the use of a vaccine delivery system
which contains the antigen and an immune potentiating
adjuvant. For instance, combination of PLGA nanoparticles
coencapsulating the poorly immunogenic melanoma anti-
gen,tyrosinase-related protein2(TRP2),alongwith Toll-like
receptor 4 ligand (TLR4) (7-acyl lipid A) led to a therapeutic
antitumor eﬀect against melanoma after the subcutaneous
administration to mice [151].
Although they do not contain synthetic peptides, some
of the licensed vaccines are comprised of a mixture of
adjuvants, such as Gardasil (composed of VLPs and alum),
Fendrix (comprising AS04, approved for human use in
Europe and USA), or Cervarix (which includes AS04 and
VLPs). These vaccines present a high immunogenicity and
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3.2. Targeting Antigens to Dendritic Cells. Vaccine delivery
systems can incorporate ligands in order to speciﬁcally target
APCs receptors. It has been shown that ligand grafting
can enhance the uptake of microparticles by immune cells.
Brandhonneur et al. [153] studied the uptake of diﬀerent
ligand-grafted PLGA microspheres by alveolar macrophages
of pigs ex vivo.T h r e ed i ﬀerent ligands were used: WGA
(lectin weat germ agglutinin, which interacts with lectin
receptors), a RGD (arginine-glycine-aspartate) containing
peptide (interacting on integrins), and a carbohydrate moi-
ety (manose-PEG3-NH2, interacting on manose receptor).
A much higher uptake was observed for mannose-, WGA-
, and RGD-grafted microspheres, mainly because of the
speciﬁc mechanism of phagocytosis. When other ligands
were grafted to the microspheres (peptideslike BSA—bovine
serum albumin or RAD—arginine-alanine-aspartame), the
uptake was not signiﬁcantly diﬀerent from ungrafted micro-
spheres, due to the nonspeciﬁc mechanism of uptake, given
the lack of receptors for BSA and RAD into macrophages.
Among PRR ligands, TLR ligands have been widely
studied. TLR activation leads to upregulation of CD40,
CD80, CD86, and CD70 costimulatory molecules in the
surface of APCs, as well as release of Th1 cytokines such
as IL-1, IL-2, IL-6, and TNF. In addition, some ligands are
able to trigger cross-presentation. Therefore, TLRs facilitate
coordination between innate and adaptive immunities by
activating B and T cells as well as memory responses [154]. It
has been shown that antigens and TLR ligands can generate
more potent immune responses when coencapsulated into
the same particle [155]. This can be understood taking
into account that endosomal organelles of DCs express
some TLRs, in addition to posses machinery to process
captured antigens and present them into MHC molecules.
Consequently, simultaneous delivery of antigen and TLR-
ligands into the cytosol may lead to a better DC activation
and subsequent development of immune response.
There exist at least 13 members of TLRs, which recognize
diﬀerent microbial components. For instance, TLR2 recog-
nize bacterial lipoproteins and lipopeptides in cooperation
with TLR1 or TLR6 [156], TLR4 binds LPS [157], TLR3
recognizes double stranded RNA [158], TLR5 attaches to
ﬂagellin [159], TLR7 and TLR8 recognize single-stranded
viral RNA [160] and synthetic imidazoquinolines [161], and
TLR9recognizesDNArichinnonmethylatedCpG(cytosine-
phosphorothioate-guanine) [162].
One of the most widely used immunopotentiating
adjuvants are those which interact with TLR9, either CpGs
present into bacterial or viral DNA or synthetic CpG
oligodeoxynucleotides (CpG ODN) [163]. Vaccination with
liposomes containing synthetic peptides derived from lym-
phocytic choriomeningitis virus (LCMV) and CpG motifs
by intramuscular route, resulted in the eﬃcient induction
of antiviral CD8+ T cell responses and complete protection
against not only LCMV but also against a highly virulent
mutant strain. Moreover, the intranasal administration
induced mucosal immunity able to protect mice from the
virus challenge, even using a low dose [164].
Other frequently used TLR ligands are those directed
to TLR3. Poly(inosinic-cytidilic) acid, that is, poly(I:C), is
a synthetic analogue of double-stranded RNA which exerts
its function via TLR3 [165]. Poly(I:C) induces maturation of
DCs [166], is a potent IFN inducer and can activate mono-
cytes and NK cells to produce proinﬂammatory cytokines
and chemokines [167]. Furthermore, poly(I:C) is able to
enhance speciﬁc antitumor immunity against synthetic
peptide-based vaccines by inducing CTL response [168],
mainly because it allows cross-priming [169]. It has been
shown that ﬂuorescent-BSA-loaded PLGA microparticles
including poly(I:C) are eﬀectively phagocytized by DCs
ex vivo and induce a maturation similar to that achieved
with a cytokine cocktail or higher concentrations of soluble
poly(I:C) [170]. Besides, murine splenic DCs pulsed with
polyketal-OVA-poly(I:C) microparticles induce higher per-
centage of IFN-γ-producing CD8+ T cells than DCs treated
with polyketal-OVA particles or soluble OVA/poly(I:C)
[171].
In addition to targeting TLRs, other delivery systems
have been prepared which target other DC receptors. These
carriers incorporate antibodies or molecules that speciﬁcally
interact with receptors such as DC-SIGN [172]o rD E C -
205 [173] and have the ability to trigger the phagocytosis
of entrapping synthetic peptides by DCs and promote their
maturation.
4.Conclusion
Vaccination with subunit vaccines comprised of synthetic
proteins and peptides is not always successful, because they
can be degraded by proteases, possess limited bioavailability,
and present relatively low immunogenicity. Delivery systems
are able to overcome these problems, since they protect
proteins from degradation and increase their bioavailability
allowing the cross of biological membranes. With regard
to immune response, delivery systems can improve and/or
modulate the response achieved with soluble peptides
alone. Although it has been proposed that they exert their
a d j u v a n c i t yb yg e n e r a t i n gad e p o te ﬀect at the injection
site, currently, other action mechanism have been found
which better explain the modulation or improvement of the
immune response. Carriers can be passively directed and
subsequently endocyted by APCs and deliver the antigen
to the cytosol or intracellular organelles. In addition, they
can interact with protein complexes, such as inﬂamma-
some, to activate immune response. Furthermore, they can
incorporate otherimmunostimulatory moleculeswhich may
improve or modulate the immune response in order to
develop not only humoral but also cellular immunity.
Delivery systems also possess other advantages; they
are safe, stable, and reproducible. Besides, they can be
administered by several routes, which oﬀer the possibility of
developing both mucosal and systemic immune responses.
All these features have led to the approval of some of
these systems to clinical use, such as VLPs, virosomes, or
traditional alum. Althoughthese adjuvantsare abletotrigger
appropriate immune responses against certain pathogens,
t h ef u t u r ei nt h i sﬁ e l dw i l lb ef o c u s e do nt h ed e v e l o p m e n t
of combined vaccines to better design the induction of an
appropriate immune response.12 Journal of Drug Delivery
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